Chadburn A, Inghirami G, Knowles D M
Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10032.
Hematol Pathol. 1992;6(3):131-41.
In this study, a clinicopathologically and immunophenotypically diverse group of T-cell neoplasms were evaluated by one- and two-color flow cytometry and/or immunohistochemistry for the presence of eight antigens (T10, T9, IL2-R, EMA, HLA-DR, LeuM1, Ki-1, and LeuM5) which are expressed in a hierarchical manner by phytohemagglutinin (PHA)-activated benign T cells. We found that 70 of the 72 T-cell neoplasms (97%) expressed at least one of these eight T-cell activation-associated antigens (T-AAgs) and that the number and type of T-AAgs expressed by the neoplastic T cells varied according to the clinicopathologic category of T-cell neoplasia. All 5 T-cell lymphoblastic malignancies expressed T10 and T9; 2 also expressed LeuM1. Twelve of 14 (86%) T cell chronic lymphocytic leukemias (T-CLL) expressed two to four T-AAgs, most frequently T10 (86%) and HLA-DR (79%). The 26 cutaneous T-cell lymphomas (CTCL) expressed between 2 and 5 T-AAgs, most commonly T9 (92%) and HLA-DR (92%), and least often T10 (12%) and EMA (15%). Twenty-six of 27 (96%) peripheral T-cell lymphomas (PTCL) expressed more than 4 T-AAgs. Each of the T-AAgs were expressed by between 22% (LeuM5) and 85% (T9) of the PTCLs. Some T-AAgs were preferentially expressed by the PTCLs in association with other T-AAgs, such as EMA in association with IL2-R and Ki-1. In addition, LeuM5 was preferentially expressed by CD4- CD8+ T-cell neoplasms. However, only 19 of the 72 (26%) T-cell neoplasms (3/5 lymphoblastic malignancies, 3/14 CLLs, 0/26 CTCLs, 13/27 PTCLs) expressed T-AAg immunophenotypic profiles paralleling those expressed by normal peripheral blood T cells activated in vitro with PHA. These results suggest that T-AAg expression by neoplastic T cells does not often mirror the hierarchical order of expression by activated benign T cells, implying that neoplastic T cells do not usually represent the precise malignant counterpart of activated benign, normal T cells.
在本研究中，通过单双色流式细胞术和/或免疫组织化学对一组临床病理和免疫表型各异的T细胞肿瘤进行评估，检测八种抗原（T10、T9、IL2-R、EMA、HLA-DR、LeuM1、Ki-1和LeuM5）的表达情况，这些抗原在植物血凝素（PHA）激活的良性T细胞中呈分层表达。我们发现，72例T细胞肿瘤中有70例（97%）表达了这八种与T细胞激活相关抗原（T-AAgs）中的至少一种，并且肿瘤性T细胞表达的T-AAgs数量和类型根据T细胞肿瘤的临床病理类别而有所不同。所有5例T细胞淋巴母细胞性恶性肿瘤均表达T10和T9；2例还表达LeuM1。14例T细胞慢性淋巴细胞白血病（T-CLL）中有12例（86%）表达2至4种T-AAgs，最常见的是T10（86%）和HLA-DR（79%）。26例皮肤T细胞淋巴瘤（CTCL）表达2至5种T-AAgs，最常见的是T9（92%）和HLA-DR（92%），最少见的是T10（12%）和EMA（15%）。27例外周T细胞淋巴瘤（PTCL）中有26例（96%）表达超过4种T-AAgs。每种T-AAg在PTCL中的表达率在22%（LeuM5）至85%（T9）之间。一些T-AAgs在PTCL中与其他T-AAgs一起优先表达，例如EMA与IL2-R和Ki-1一起表达。此外，LeuM5在CD4-CD8+T细胞肿瘤中优先表达。然而，72例T细胞肿瘤中只有19例（26%）（5例淋巴母细胞性恶性肿瘤中的3例、14例CLL中的3例、26例CTCL中的0例、27例PTCL中的13例）表达的T-AAg免疫表型谱与体外经PHA激活的正常外周血T细胞所表达的谱型相似。这些结果表明，肿瘤性T细胞的T-AAg表达通常并不反映激活的良性T细胞的分层表达顺序，这意味着肿瘤性T细胞通常并非激活的良性正常T细胞的确切恶性对应物。
